Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.3 USD | +6.98% | +9.52% | -65.85% |
Financials (USD)
Sales 2022 | 13.48 | Sales 2023 | 15.77 | Capitalization | 9.96M |
---|---|---|---|---|---|
Net income 2022 | -96M | Net income 2023 | -75M | EV / Sales 2022 | -836,796 x |
Net cash position 2022 | 63.29M | Net Debt 2023 | 15.36M | EV / Sales 2023 | 1,605,487 x |
P/E ratio 2022 |
-0.51
x | P/E ratio 2023 |
-0.13
x | Employees | 25 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.23% |
Latest transcript on Eiger BioPharmaceuticals, Inc.
1 day | +6.98% | ||
1 week | +9.52% | ||
1 month | -4.17% | ||
3 months | -67.14% | ||
6 months | -77.45% | ||
Current year | -65.85% |
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
James Vollins
CMP | Compliance Officer | 55 | 23-04-12 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-07-17 | |
Thomas Dietz
CHM | Chairman | 60 | 16-03-21 |
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.00% | 17 M€ | +4.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 2.3 | +6.98% | 5,382 |
24-05-30 | 2.15 | -0.92% | 1,935 |
24-05-29 | 2.17 | -1.36% | 5,482 |
24-05-28 | 2.2 | +4.76% | 19,986 |
Delayed Quote OTC Markets, May 31, 2024 at 03:58 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-65.85% | 3.41M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- EIGR Stock